• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Meta-Analysis: Which Interventions are Best for Preventing Spontaneous Preterm Birth?  

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Care et al. (BMJ, 2022) performed a network meta-analysis of various treatment options for the prevention of spontaneous preterm birth in at-risk women  

METHODS: 

  • Systematic review with Bayesian network meta-analysis
  • Study inclusion criteria
    • RCTs
    • Study participants who are at high risk of spontaneous preterm birth due to history of spontaneous preterm birth or short cervical length
    • Data included assessment of treatment options
  • Study design
    • Treatments: Bed rest | Cervical cerclage (McDonald, Shirodkar, or unspecified type of cerclage) | Cervical pessary | Fish oils or omega fatty acids | Nutritional supplements (zinc) | Progesterone (intramuscular, oral, or vaginal) | Prophylactic antibiotics | Prophylactic tocolytics | Combinations of interventions
    • Controls: Placebo or no treatment
    • Relative treatment effects (odds ratios and 95% credible intervals) and certainty of evidence were calculated for outcomes of preterm birth <34 weeks and perinatal death
  • Primary outcome
    • Preterm birth <34 weeks
    • Perinatal death
    • Other maternal and fetal outcomes

RESULTS: 

  • 61 studies | 17,273 pregnant women

Preterm Birth <34 weeks

  • Compared to placebo or no treatment, vaginal progesterone was associated with fewer women with preterm birth <34 weeks
    • Odds ratio (OR) 0.50 (95% CrI, 0.34 to 0.70); high certainty of evidence
  • Effect size of treatment was highest for Shirodkar cerclage, but certainty was low
    • OR 0.06 (95% CrI, 0.00 to 0.84); low certainty of evidence
  • The following treatments may also reduce preterm birth <34 weeks
    • 17OHPC (17α-hydroxyprogesterone caproate)
      • OR 0.68 (95% CrI, 0.43 to 1.02); moderate certainty
    • Vaginal pessary
      • OR 0.65 (95% CrI, 0.39 to 1.08); moderate certainty
    • Fish oil or omega 3
      • OR 0.30 (95% CrI, 0.06 to 1.23); moderate certainty

Perinatal death

  • Compared to placebo or no treatment, vaginal progesterone was the only treatment that showed clear evidence of benefit for reducing perinatal death
    • OR 0.66 (95% CrI, 0.44 to 0.97); moderate certainty
  • The following treatments might reduce perinatal death rates, but credible intervals could not exclude the possibility of harm
    • 17OHPC
      • OR 0.78 (95% CrI, 0.50 to 1.21); moderate certainty
    • McDonald cerclage
      • OR 0.59 (95% CrI, 0.33 to 1.03); moderate certainty
    • Unspecified cerclage
      • OR 0.77 (95% CrI, 0.53 to 1.11); moderate certainty
  • Only progesterone treatments are associated with reduction the following neonatal outcomes
    • Neonatal respiratory distress syndrome
    • Neonatal sepsis
    • Necrotizing enterocolitis
    • Admission to neonatal intensive care unit

CONCLUSION: 

  • Vaginal progesterone is the best preventative treatment option for asymptomatic women at risk of preterm birth due to short cervix and history of preterm birth 
  • The authors suggest that future trials use vaginal progesterone as the ‘gold standard’ comparator group when assessing other treatment options 
    • Administering placebo or no treatment will be difficult to offer 
  • The authors state 

Vaginal progesterone is currently the best preterm birth prevention treatment for women with a singleton pregnancy who are asymptomatic but at high risk of preterm birth 

No other treatment can be regarded as superior, but promising results have been observed for alternative routes of administration (oral, intramuscular), and treatments such as cerclage and pessary 

Learn More – Primary Sources: 

Interventions to prevent spontaneous preterm birth in women with singleton pregnancy who are at high risk: systematic review and network meta-analysis 

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

EPPPIC Meta-analysis Results: Progestogens for Preterm Birth Prevention
Progesterone or Cerclage in Preterm Prevention in Women with Previous Preterm Birth and Short Cervix?
EVENTS RCT Results: Does Vaginal Progesterone for Women with Twin Pregnancies Reduce Incidence of Preterm Birth?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site